Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI   US72940R1023

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/16/2014 12/17/2014 12/18/2014 12/19/2014 12/22/2014 Date
2.47(c) 2.51(c) 2.51(c) 2.5(c) 2.52 Last
115 565 100 108 132 047 162 862 195 396 Volume
-2.76% +1.62% 0.00% -0.40% +0.80% Change
More quotes
Company
Pluristem Therapeutics, Inc. is a bio-therapeutic company, which develops standardized cell therapy products for the treatment of life threatening diseases.The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 0,38 M
EBIT 2015 -30,2 M
Net income 2015 -36,7 M
Debt 2015 -
Yield 2015 -
Sales 2016 10,3 M
EBIT 2016 -29,7 M
Net income 2016 -33,1 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 465x
Capi. / Sales 2016 17,1x
Capitalization 175 M
More Financials
Latest news on PLURISTEM THERAPEUTICS INC
14h ago PLURISTEM THERAPEUTICS : New Published Data Show Pluristem’s PLX Cells Pro..
4d ago PLURISTEM THERAPEUTICS INC. : When Considering Cell Therapy Investments - Not Al..
12/04 PLURISTEM THERAPEUTICS : and Hadassah Medical Center Will Collaborate to Study P..
12/03 PLURISTEM THERAPEUTICS : Granted Patent in Singapore for Its 3D Cell Expansion T..
12/01 PLURISTEM THERAPEUTICS : Dr. Ohad Karnieli to Present at Two Upcoming Scientific..
12/01 PLURISTEM THERAPEUTICS : Granted Patent in Singapore for Its 3D Cell Expansion T..
11/21 PLURISTEM THERAPEUTICS : posts 1Q loss
11/12 PLURISTEM THERAPEUTICS : Granted Patents in Australia and New Zealand for Use of..
More news
Sector news
1h ago MEDIVATION : Exercises License Option for Pidilizumab
4h ago MONDAY'S ETF MOVERS : Eem, bbh
8h ago PHARMACYCLICS : Announces Update on IMBRUVICA® (ibrutinib) Waldenstrom's macrogl..
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF